Vident Investment Advisory, LLC Inhibrx, Inc. Transaction History

Vident Investment Advisory, LLC

  • $0
  • Q3 2023

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 15, 2023
SELL
$18.45 - $27.14 $16,033 - $23,584
-869 Reduced 3.33%
25,199 $475,000
Q4 2022

Feb 14, 2023
BUY
$20.18 - $33.33 $526,052 - $868,846
26,068 New
26,068 $642,000
Q2 2022

Aug 15, 2022
SELL
$8.52 - $25.26 $229,528 - $680,504
-26,940 Closed
0 $0
Q1 2022

May 16, 2022
BUY
$19.89 - $43.18 $89,306 - $193,878
4,490 Added 20.0%
26,940 $600,000
Q4 2021

Feb 14, 2022
BUY
$26.75 - $46.02 $600,537 - $1.03 Million
22,450 New
22,450 $980,000

Others Institutions Holding INBX

# of Institutions
1
Shares Held
18.6K
Call Options Held
0
Put Options Held
0
View Full List

About Inhibrx, Inc.

INBX Quotes by TradingView
  • Ticker INBX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 39,057,700
  • Market Cap $565M
  • Description
  • Inhibrx, Inc., a clinical-stage biotechnology company, focuses on developing a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidates include INBRX-109, a tetravalent agonist of death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, and pancreatic adenocarcin...
More about INBX
Track This Portfolio

Track Vident Investment Advisory, LLC Portfolio

Follow Vident Investment Advisory, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vident Investment Advisory, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Vident Investment Advisory, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email